Aurobindo Pharma share news, announcements and annual reports
NSE: AUROPHARMABSE: 524804Pharmaceuticals & BiotechnologyMid Cap
Aurobindo Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, Jul 2000 on NSE
Last close ₹1,681.40up ₹21.50 (1.30%)BSE ₹1,677.80
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,659.90.
30 Oct: open ₹1,652.00, high ₹1,687.00, low ₹1,647.20
52-week range of traded prices to 30 Oct 2026
₹1,091.20Low, 30 Oct 2025₹1,740.00High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹96,744 Cr138th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.06
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.55
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 9,52,65057.5% delivered
Aurobindo Pharma share news and announcements
1,689 announcements, routine notices left out, newest first. Page 26 of 34.
Jan 2013
9 Jan · Disclosure
Compensation Committee of the Board at its meeting held on January 09, 2013, has considered and approved grant of 5,00,000 options at an exercise price of Rs.200.70 per option (each option confer a right to one equity share of Re.1/- each) under the Employees Stock Option Plan, 2006.9 Jan · Business
Compensation Committee of the Board at the meeting held on January 09, 2013 has made allotment of 90,000 Equity Shares of Re.1/- each at a premium of Rs.90.60 per share under ESOP-2006 Scheme of the Company. Consequent to the allotment the paid up share capital of the Company has increased from 29,11,21,290 Equity Shares of Rs.1/- each to 29,12,11,290 Equity Shares of Re.1/- each.
Dec 2012
Nov 2012
9 Nov · Management
Mr.Ravindra Y Shenoy, Joint Managing Director of the Company has tendered his resignation due to his unavoidable personal family reasons. The Board of Directors of the Company at their meeting held on November 09, 2012 have accepted his resignation and consented to relieve Mr.Shenoy of his duties and responsibilities vested by the Board as Director & Joint Managing Director of the Company, with effect from the close of working hours on November 09, 20129 Nov · Results
Consolidated Results for the quarter ended on 30-SEP-2012 as follows: Net Sales of Rs. 148105 lacs for the quarter ending on 30-SEP-2012 against Rs. 119744 lacs and Rs. 107530 lacs for the quarters ending on 30-JUN-2012 and 30-SEP-2011 respectively. Net Profit / (Loss) of Rs. 22235 lacs for the quarter ending on 30-SEP-2012 against Rs. (12891) lacs and Rs. (8016) lacs for the quarters ending on 30-JUN-2012 and 30-SEP-2011 respectively.9 Nov · Results
Standalone Results for the quarter ended on 30-SEP-2012 as follows: Net Sales of Rs. 137248 lacs for the quarter ending on 30-SEP-2012 against Rs. 111256 lacs and Rs. 95769 lacs for the quarters ending on 30-JUN-2012 and 30-SEP-2011 respectively. Net Profit / (Loss) of Rs. 23801 lacs for the quarter ending on 30-SEP-2012 against Rs. (4984) lacs and Rs. (4188) lacs for the quarters ending on 30-JUN-2012 and 30-SEP-2011 respectively.
Oct 2012
23 Oct · Board meeting
To consider inter alia, the Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2012.
Sep 2012
28 Sep · Disclosure of Voting Pattern - Clause 35A
14 Sep · Legal
Dated September 14, 2012 that "In response to news appearing in certain section of the press about Aurobindo considering restructuring by way of sale of some of its unit(s) or verticals is completely groundless, false and untrue. We completely deny all these rumors and caution all shareholders and investors not to take cognizance of these rumors. Aurobindo prides itself of its strong vertical integration and will continue to unleash potential of its vertical integration to market leadership and competitiveness".
Aug 2012
10 Aug · Management
Dr. P.L. Sanjeev Reddy a Non-Executive and Independent Director ceased to be Director of the Company consequent to his non seeking reappointment at the Annual General Meeting of the Company held on August 07, 2012.8 Aug · Disclosure of Voting Pattern - Clause 35A
7 Aug · Results
Consolidated Results for the quarter ended on 30-JUN-2012 as follows: Net Sales of Rs. 119744 lacs for quarter ending on 30-JUN-2012 against Rs. 107687 lacs for the quarter ending on 30-JUN-2011. Net Profit / (Loss) of Rs. (12891) lacs for the quarter ending on 30-JUN-2012 against Rs. (12280) lacs for the quarter ending on 30-JUN-2011.7 Aug · Results
Standalone Results for the quarter ended on 30-JUN-2012 as follows: Net Sales of Rs. 111256 lacs for quarter ending on 30-JUN-2012 against Rs. 103014 lacs for the quarter ending on 30-JUN-2011. Net Profit / (Loss) of Rs. (4984) lacs for the quarter ending on 30-JUN-2012 against Rs. (10158) lacs for the quarter ending on 30-JUN-2011.
Jul 2012
23 Jul · Board meeting
To consider inter alia, the Un-Audited Financial Results of the Company for the quarter ended June 30, 2012.